ETS rearrangements in prostate cancer  

前列腺癌中ETS重排

作　　者：Mark A Rubin 

机构地区：[1]Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA

出　　处：《Asian Journal of Andrology》2012年第3期393-399,I0005,共8页亚洲男性学杂志（英文版）

摘　　要：Prostate cancer is a clinically and molecularly heterogeneous disease. Understanding the biologic underpinning of prostate cancer is necessary to best determine how biology is associated with the risk of disease progression and how this understanding might provide insight into the development of novel therapeutic approaches. The focus of this review is on the recently identified common ETSand non-ETS gene rearrangements in prostate cancer. Although multiple molecular alterations have been detected in prostate cancer, a basic understanding of gene fusion prostate cancer should help explain the clinical and biologic diversity, providing a rationale for a molecular subclassification of the disease.Prostate cancer is a clinically and molecularly heterogeneous disease. Understanding the biologic underpinning of prostate cancer is necessary to best determine how biology is associated with the risk of disease progression and how this understanding might provide insight into the development of novel therapeutic approaches. The focus of this review is on the recently identified common ETSand non-ETS gene rearrangements in prostate cancer. Although multiple molecular alterations have been detected in prostate cancer, a basic understanding of gene fusion prostate cancer should help explain the clinical and biologic diversity, providing a rationale for a molecular subclassification of the disease.

关 键 词：ETS gene fusion next generation sequencing prostate cancer TMPRSS2.ERG TRANSLOCATION 

分 类 号：R[医药卫生]